Pfizer Starts Testing Pneumococcal Vaccine Candidate Along With COVID-19 Booster Shot - Pfizer (NYSE:PFE), BioNTech (NASDAQ:BNTX)

Pfizer Inc PFE has started testing fully vaccinated adults over 65 in a new study exploring the company's 20-valent pneumococcal conjugate vaccine (20vPnC) candidate after a third dose of the Pfizer-BioNTech SE BNTX COVID-19 shot.
The primary objective of the trial is to assess safety with a follow-up six months after vaccination.
Secondary objectives are to describe immune responses produced by each of the vaccines.
The vaccine candidate, 20vPnC, is being developed to help protect adults against 20 serotypes responsible for the majority of invasive pneumococcal disease and pneumonia.
The new study will include 600 adults recruited from the two companies' late-stage COVID-19 vaccine study after receiving their second dose of the vaccine at least six months before entering the co-administration study.
In December, the FDA accepted 20vPnC's application in adults over 18 and set an action date for a decision in June. The European Medicines Agency (EMA) accepted the company's application for 20vPnC in February.
Price Action: PFE shares are up 0.15% at $40.01, and BNTX is up 0.92% at $197.50 during the premarket session on the last check Monday.